“…Results of the RIPHeart (Remote Ischaemic Preconditioning for Heart Surgery) trial, in which AKI was a component of the primary end point, are eagerly awaited. 18 Interestingly, RIPC has been reported to confer renoprotection in several other clinical settings, including major vascular surgery, 19,20 elective percutaneous coronary intervention for stable coronary artery disease, 21,22 primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction, 23,24 and kidney transplantation, 25 although again, not all studies have been positive. 26,27 WHAT SHOULD CLINICIANS AND RESEARCHERS DO?…”